Startseite/Aktien/ZVSA

ZVSA

USD

ZyVersa Therapeutics Inc. Common Stock

$0.145+0.009 (6.618%)

Echtzeitkurs

Healthcare

Biotechnologie

Vereinigte Staaten

Kursdiagramm

Loading Chart...

Schlüsselkennzahlen

Marktkennzahlen

Unternehmensfundamentaldaten

Handelsstatistiken

Marktkennzahlen

Eröffnung

$0.136

Hoch

$0.145

Tief

$0.136

Volumen

0.00M

Unternehmensfundamentaldaten

Marktkapitalisierung

1.2M

Branche

Biotechnologie

Land

United States

Handelsstatistiken

Durchschnittliches Volumen

0.04M

Börse

OQB

Währung

USD

52-Wochen-Spanne

Tief $0.11Aktuell $0.145Hoch $1.95

Ähnliche Nachrichten

10. Sept. 2025 · 11:55

GlobeNewswire

ZyVersa Therapeutics Highlights Data Reinforcing the Potential of Inflammasome Inhibitors to Attenuate Progression of Type 2 Diabetes and Improve Associated Long-term Cardiovascular Outcomes

Type 2 diabetes (T2DM), affecting more than 530 million worldwide, is a metabolic disease often coupled with cardiovascular complications including coronary artery disease, heart failure, and stroke.Cardiovascular

ZyVersa Therapeutics Highlights Data Reinforcing the Potential of Inflammasome Inhibitors to Attenuate Progression of Type 2 Diabetes and Improve Associated Long-term Cardiovascular Outcomes

3. Sept. 2025 · 11:55

GlobeNewswire

ZyVersa Therapeutics Highlights Lipidomic Data in Alport Syndrome and DKD Reinforcing the Need for Drugs to Attenuate Damaging Renal Lipid Accumulation to Mitigate Disease Progression

ZyVersa is developing Cholesterol Efflux Mediator™ VAR 200 to mediate removal of damaging excess cholesterol and other lipids from the kidneys' filtration system. VAR 200 directly removes lipids from kidney cells,